Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug
A. R. Decker-Farrell, S. A. Sastra, T. Harimoto, M. C. Hasselluhn, C. F. Palermo, E. R. Ballister, M. A. Badgley, T. Danino, K. P. Olive
This study engineers a probiotic bacteria to selectively target pancreatic cancer, improving survival and modulating the tumor microenvironment.
bioRxiv · May 2, 2024 · PreprintCancer Biology